PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-11.25
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.00. Seth Klarman would scrutinize path to profitability versus peers.
6.21
P/S 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 4.53. Guy Spier would scrutinize if premium reflects durable advantages.
0.41
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.12. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
65.81
P/FCF of 65.81 versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.
45.90
P/OCF of 45.90 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
0.41
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.14. Joel Greenblatt would investigate if this discount is justified.
-2.22%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.48%. Seth Klarman would investigate path to profitability.
1.52%
FCF yield of 1.52% versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.
